Early data indicate Voranigo (vorasidenib) is being rapidly adopted in patients with isocitrate dehydrogenase–mutated glioma, ...
Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC)—a leading research partner of the NCI-designated ...
Le 17 novembre 2025, Rigel Pharmaceuticals, Inc. a annoncé la publication, après évaluation par des pairs, des données finales sur cinq ans issues de la cohorte pivot de l'essai ...
NeOnc Technologies Holdings, Inc. a annoncé avoir terminé l'inclusion de l'ensemble des patients dans son essai clinique de ...
A new study reveals that impaired brain fluid flow in regions opposite the tumor predicts shorter survival in glioblastoma, ...
Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously ...
Rigel Pharmaceuticals (RIGL) announced a peer-reviewed publication in the Journal of Hematology & Oncology of the final five-year data from the ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...
The Nexus of Open Science symposium took place on Nov. 14, bringing together leaders in neuroscience, clinical research, ...
Primary central nervous system (CNS) tumors pose significant challenges due to their heterogeneous nature, frequently limited prognosis, and substantial impact on quality of life. Despite advances in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback